Toxicology – Atropine

Core Concept

Atropine is a competitive muscarinic acetylcholine receptor antagonist.

In toxicology, its most important role is treatment of the dangerous muscarinic manifestations of cholinergic poisoning, particularly from:

• Organophosphate pesticides
• Carbamate pesticides
• Nerve agents
• Other clinically important cholinesterase inhibitors

Atropine is also used in selected cases of symptomatic bradycardia.

Mechanism of Action

Atropine competitively blocks acetylcholine at muscarinic receptors.

This decreases parasympathetic activity in organs such as the:

• Heart
• Bronchial tree
• Salivary glands
• Gastrointestinal tract
• Urinary tract
• Eyes
• Sweat glands

The clinically important toxicologic effect is:

Muscarinic receptor blockade → reduced bronchial secretions and bronchoconstriction

Muscarinic vs Nicotinic Effects

This distinction is essential in cholinergic poisoning.

Muscarinic manifestations

Atropine is effective against:

• Bronchorrhea
• Bronchospasm
• Excess salivation
• Lacrimation
• Bradycardia
• Some GI hyperactivity

Nicotinic manifestations

Atropine does not directly reverse:

• Fasciculations
• Skeletal muscle weakness
• Paralysis
• Respiratory muscle failure

Therefore, improvement in secretions does not necessarily mean the entire cholinergic syndrome has resolved.

Central Nervous System Effects

Atropine crosses the blood-brain barrier.

At sufficient exposure it can produce central antimuscarinic effects such as:

• Agitation
• Confusion
• Delirium
• Hallucinations

This differs from quaternary antimuscarinic drugs such as glycopyrrolate, which have much less CNS penetration.

Main Toxicologic Indication: Cholinergic Poisoning

Severe cholinesterase inhibitor poisoning may produce:

• Miosis
• Salivation
• Lacrimation
• Bronchorrhea
• Bronchospasm
• Vomiting
• Diarrhea
• Sweating
• Bradycardia or tachycardia
• Fasciculations
• Weakness
• Seizures
• Respiratory failure

The major immediate threat is often respiratory compromise from a combination of:

• Copious airway secretions
• Bronchoconstriction
• Respiratory muscle weakness
• CNS dysfunction

Atropine primarily treats the first two components.

Atropine Treatment Endpoint

In severe cholinergic poisoning, atropine should be titrated according to the clinical response, particularly the respiratory findings.

The important endpoint is:

Improved ventilation with substantial control of bronchial secretions and bronchospasm

Useful signs include:

• Drying of excessive pulmonary secretions
• Improved air movement
• Improved oxygenation
• Improved hemodynamic status when muscarinic effects contributed

Do Not Use Pupil Size as the Endpoint

Miosis may persist despite adequate treatment.

Therefore:

Pupil dilation is not required for successful atropinization.

Attempting to normalize pupil size can lead to unnecessary atropine administration.

Do Not Use Heart Rate Alone as the Endpoint

Tachycardia is common during atropine therapy, but it does not necessarily mean treatment should stop.

A patient may still have life-threatening bronchorrhea despite being tachycardic.

Therefore:

Pulmonary secretion control and ventilation are more important endpoints than heart rate alone.

Organophosphate Poisoning

Organophosphates inhibit acetylcholinesterase, producing accumulation of acetylcholine at:

• Muscarinic synapses
• Nicotinic synapses
• CNS cholinergic pathways

Atropine competitively blocks the muscarinic consequences of this acetylcholine excess.

It does not reactivate acetylcholinesterase.

Role of Pralidoxime

In significant organophosphate poisoning, pralidoxime may be used in addition to atropine.

The two drugs have different roles:

Atropine

Controls muscarinic manifestations, especially:

• Bronchorrhea
• Bronchospasm
• Bradycardia

Pralidoxime

Can reactivate inhibited acetylcholinesterase before irreversible enzyme “aging” occurs and may particularly help with:

• Fasciculations
• Muscle weakness
• Respiratory muscle dysfunction

Atropine should not be delayed while waiting for pralidoxime.

Carbamate Poisoning

Carbamates also inhibit acetylcholinesterase but generally bind reversibly.

Atropine remains the primary treatment for clinically important muscarinic toxicity.

The role of pralidoxime is less straightforward than in organophosphate poisoning and depends on the specific exposure and clinical circumstances.

Nerve-Agent Exposure

Nerve agents are potent organophosphorus cholinesterase inhibitors.

Severe exposure may cause rapid:

• Bronchorrhea
• Bronchospasm
• Seizures
• Fasciculations
• Paralysis
• Respiratory failure

Management may require:

• Airway and ventilatory support
• Atropine
• An oxime such as pralidoxime
• Benzodiazepines for seizures

Symptomatic Bradycardia

Atropine can increase heart rate by reducing parasympathetic influence on the:

• Sinoatrial node
• AV node

It may be appropriate for selected symptomatic bradycardias associated with poor perfusion.

However, atropine is not equally effective for every toxicologic bradycardia.

Toxicologic Bradycardias

Important causes include:

• Beta-blockers
• Calcium channel blockers
• Digoxin
• Clonidine/imidazolines
• Cholinergic agents
• Opioids

In many of these poisonings, atropine may provide little or only transient benefit.

The priority is the toxin-specific mechanism and treatment.

Examples include:

• Digoxin toxicity → digoxin immune Fab when indicated
• Severe beta-blocker/CCB toxicity → mechanism-directed cardiovascular support
• Opioid toxicity → naloxone when respiratory depression is present
• Cholinergic poisoning → atropine is directly relevant

Expected Antimuscarinic Effects

Atropine itself can produce:

• Tachycardia
• Mydriasis
• Cycloplegia
• Dry mouth
• Reduced sweating
• Flushed skin
• Reduced bowel motility
• Urinary retention

Larger exposures may cause:

• Hyperthermia
• Agitation
• Hallucinations
• Delirium

These findings represent an anticholinergic syndrome.

Hyperthermia Risk

Atropine decreases sweating.

Because sweating is important for heat dissipation, antimuscarinic therapy can increase susceptibility to hyperthermia, particularly in:

• Hot environments
• Young children
• Patients already hyperthermic
• Patients receiving other anticholinergic medications

Temperature should therefore be monitored during substantial atropine therapy.

Ophthalmic Effects

Topical atropine causes:

Mydriasis

Dilation of the pupil.

Cycloplegia

Paralysis of accommodation.

The ocular effects can persist considerably longer than atropine’s cardiovascular effects.

Possible consequences include:

• Photophobia
• Blurred near vision
• Increased intraocular pressure in susceptible patients

Angle-Closure Glaucoma

Ophthalmic antimuscarinic medications can precipitate or worsen acute angle closure in anatomically susceptible eyes.

This is particularly relevant when atropine is being used specifically as an ophthalmic medication.

In a life-threatening systemic poisoning, however, relative contraindications should not prevent necessary antidotal atropine treatment.

Systemic Absorption from Eye Drops

Atropine administered ophthalmically can be absorbed systemically.

Systemic anticholinergic effects are more concerning in:

• Children
• Older adults
• Patients receiving excessive topical medication

Possible manifestations include:

• Tachycardia
• Dry mouth
• Flushing
• Hyperthermia
• Confusion

Drug Interactions

Atropine’s antimuscarinic effects may be increased by other medications with anticholinergic properties, including certain:

• First-generation antihistamines
• Antipsychotics
• Tricyclic antidepressants
• Antiparkinsonian drugs
• Antispasmodic medications

Combining substantial anticholinergic burdens can increase the risk of:

• Delirium
• Hyperthermia
• Urinary retention
• Ileus
• Tachycardia

The older source’s description of sympathomimetics simply “potentiating atropine” is an oversimplification; rather, their physiologic effects can overlap, particularly tachycardia and hyperthermia.

Atropine Toxicity

Excess atropine produces an antimuscarinic toxidrome.

Typical findings include:

• Mydriasis
• Dry mucous membranes
• Dry skin
• Flushing
• Tachycardia
• Hyperthermia
• Urinary retention
• Reduced bowel sounds
• Agitation
• Delirium
• Hallucinations

Severe poisoning can cause marked CNS and cardiovascular abnormalities.

Physostigmine and Atropine Toxicity

Physostigmine is a centrally active acetylcholinesterase inhibitor that can reverse selected severe pure antimuscarinic delirium.

However, it is not automatically appropriate whenever atropine-like symptoms occur.

Before considering it, clinicians must exclude important contraindications and alternative causes, particularly:

• Sodium-channel-blocking poisoning
• Significant QRS widening
• Certain conduction abnormalities
• Mixed overdose

Supportive care remains fundamental.

Atropine Administration in Severe Cholinergic Poisoning

Severe organophosphate poisoning may require very large cumulative quantities of atropine compared with ordinary bradycardia treatment.

The principle is more important than memorizing a fixed maximum:

Escalate atropine rapidly enough to control life-threatening muscarinic pulmonary toxicity.

Once adequate control is achieved, ongoing therapy may be required because the toxicant can persist much longer than atropine.

Exact dosing should follow current poison-center or critical-care protocols.

Recurrent Cholinergic Toxicity

Atropine’s clinical effect may wear off while the cholinesterase inhibitor remains active.

Therefore, patients can develop recurrent:

• Bronchorrhea
• Bronchospasm
• Bradycardia
• Other muscarinic manifestations

Continued reassessment is essential.

Monitoring

During significant atropine treatment, monitor:

• Airway
• Respiratory effort
• Pulmonary secretions
• Oxygenation
• Heart rate and rhythm
• Blood pressure
• Temperature
• Mental status
• Bowel and urinary function when relevant

In cholinergic poisoning, also monitor for:

• Fasciculations
• Progressive weakness
• Respiratory muscle failure
• Recurrent secretions

Pregnancy

The historical FDA pregnancy categories such as Category C are obsolete.

When atropine is required for a serious maternal indication, including significant cholinergic poisoning, pregnancy should not prevent necessary treatment.

Maternal stabilization remains the priority.

Common Pitfalls

Stopping atropine because tachycardia develops

Tachycardia does not prove that pulmonary muscarinic toxicity has resolved.

Waiting for the pupils to dilate

Pupil size is not the treatment endpoint.

Expecting atropine to reverse muscle weakness

Nicotinic neuromuscular dysfunction is not directly reversed by atropine.

Giving atropine but ignoring ventilation

Patients with severe organophosphate poisoning can still require airway and ventilatory support.

Using a fixed maximum dose in severe poisoning

Massive cholinergic toxicity may require unusually large cumulative atropine exposure.

Assuming every toxicologic bradycardia will respond

Many cardiotoxic poisons require specific therapies beyond atropine.

Important Modernization of the Older Source

Several points from the original material require updating:

• Atropine is best described specifically as an antimuscarinic, rather than broadly as an “anticholinergic antidote.”
• Its most important endpoint in cholinergic poisoning is control of bronchorrhea/bronchospasm and improvement in ventilation, not normalization of pupil size or heart rate.
• Atropine does not treat nicotinic weakness or paralysis.
• Severe organophosphate poisoning may require very large amounts, with treatment guided by clinical response rather than a conventional maximum dose.
• Pralidoxime has a complementary role in significant organophosphate poisoning.
• Atropine is not reliably effective for all poison-induced bradycardias.
• Routine atropine as a premedication for pediatric procedural sedation is not standard modern practice.
• FDA pregnancy letter categories are obsolete.
• Sympathomimetics do not simply “potentiate atropine”; rather, several physiologic effects can overlap.
• Relative contraindications to atropine should not prevent its use when treating life-threatening cholinergic poisoning.

Key Points

• Atropine is a competitive muscarinic acetylcholine receptor antagonist.
• It has little direct effect at nicotinic receptors.
• Its major toxicologic use is treatment of muscarinic cholinergic toxicity.
• It is especially important for bronchorrhea and bronchospasm caused by organophosphates, carbamates, and nerve agents.
• The major treatment endpoint is adequate ventilation with control of excessive pulmonary secretions.
• Do not titrate atropine to pupil size.
• Do not stop treatment merely because tachycardia develops.
• Atropine does not directly reverse fasciculations, skeletal muscle weakness, or paralysis.
• Pralidoxime complements atropine in significant organophosphate poisoning by targeting the inhibited acetylcholinesterase mechanism.
• Severe cholinergic poisoning may require unusually large cumulative atropine exposure.
• Atropine can treat selected symptomatic bradycardias, but many toxicologic bradycardias require toxin-specific treatment.
• Excess atropine causes an antimuscarinic syndrome with tachycardia, mydriasis, dry skin/mucosa, urinary retention, hyperthermia, and delirium.
• Significant cholinergic poisoning requires continued monitoring because toxicity may recur after atropine’s effects diminish.